If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTP ICAP Regulatory News (TCAP)

Share Price Information for TP ICAP (TCAP)

Share Price is delayed by 15 minutes
Get Live Data
351.00    0.40 (0.11%)
Bid:
350.80
Ask:
351.20
Spread: 0.40 (0.114%)
Market Cap: £2.56b
TCAP Live PriceLast checked at - London Stock Exchange

Intraday TP ICAP Share Chart

Update on Brexit Readiness Plan

25 Jan 2021 07:00

RNS Number : 6897M
TP ICAP PLC
25 January 2021
 

TP ICAP PLC

 

25 January 2021

 

TP ICAP plc ("TP ICAP" or the "Group")

 

Update on Brexit Readiness Plan

 

In the prospectus published by TP ICAP plc dated 7 January 2021 in connection with its proposed rights issue (the Rights Issue Prospectus) and the prospectus published by TP ICAP Group plc dated 7 January 2021 in connection with the proposed re-domiciliation of the Group to Jersey (the Re-domiciliation Prospectus, and together with the Rights Issue Prospectus, the Prospectuses), it was stated that, "Following discussions with its lead regulators, the Group believes that, as a temporary measure, those lead regulators will allow the Group to continue to provide services to clients based in the 27 countries of the EU using London-based brokers acting on behalf of its UK-regulated entities, in order to support the stability and connectivity of the markets".

 

Following publication of the Prospectuses, on 22 January 2021, TP ICAP's regulators in France, the AMF and the ACPR, published a statement in respect of brokerage firms addressing Brexit implementation issues (the Statement). In the Statement, the AMF and the ACPR:

· noted that, as of 1 January 2021, EU law is no longer applicable in the UK and that European regulations no longer allow for the supply of investment services into the EEA through brokers located in the UK and acting on behalf of a UK entity;

· noted that entities located in the UK that wish to provide investment services into the EEA should establish an authorised branch or subsidiary there, which must have sufficient staff to ensure prudent risk management and effective supervision of their activities;

· set out their expectation that entities complete relocation plans that are being implemented as soon as possible and finalise transfers of persons who have not yet been relocated; and

· pointed out that an entity providing investment services in the EEA without proper approval or in accordance with the limited exceptions provided in national law is at risk of administrative or criminal prosecution under the law of each Member State.

As stated in the Prospectuses, as part of its Brexit readiness plan, TP ICAP has established and capitalised a new authorised subsidiary in France, TP ICAP Europe S.A. (TPIE), to undertake the Group's broking business in EU 27 member states (the EU 27). However, due partly to the extraordinary circumstances relating to the COVID-19 pandemic, in particular relating to stay-at-home orders and travel restrictions currently in effect, it has not yet been possible to complete the relocation of staff to the EU 27 or the local hiring of brokers in the EU-based offices of TPIE as quickly as originally planned. In response to the Statement, TP ICAP confirms its commitment to complete the relocation of staff to the EU 27 and the local hiring of staff in the EU-based offices of TPIE at the earliest opportunity.

Following the loss of the EU passporting rights, TP ICAP's UK-based authorised subsidiaries no longer have the full scope of necessary regulatory permissions to service all clients based in the EU 27. TP ICAP's UK-based authorised subsidiaries continue to service clients based in certain EU 27 member states where possible under available temporary permission regimes, existing third country access rights, or as otherwise permitted by applicable laws and regulations.

TP ICAP believes that the successful implementation of its Brexit readiness plan will ensure a robust and sustainable future operating platform for servicing EU 27-based clients, notwithstanding the fact that the regimes for the cross border provision of financial services from the UK to the EU 27 may evolve further during 2021.

 

TP ICAP does not expect any material impact on the Group's global broking business or its financial results as a result of any of the matters disclosed above, including any temporary reduction of services provided to clients based in the EU 27.

 

TP ICAP confirms that supplementary prospectuses in respect of the Rights Issue Prospectus and the Re-domiciliation Prospectus will be submitted to the Financial Conduct Authority (the FCA) for approval and, once approved by the FCA, will be published and made available on the Company's website, free of charge, at www.tpicap.com/investors and at the Company's registered office at Level 2, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom. The Group expects the rights issue and re-domiciliation to proceed on the timetables set out in the Prospectuses.

 

For further information:

 

Analysts and investors:

 

· Al Alevizakos, Head of Investor Relations Mobile: +44 (0) 79 9991 2672

E-mail: Alevizos.Alevizakos@tpicap.com

 

Media:

 

· William Baldwin-Charles, Media Relations DirectorMobile: +44 (0) 78 3452 4833

E-mail: William.Baldwin-Charles@tpicap.com

 

· Neil Bennett, Maitland

Direct: +44 (0) 20 7379 5151

E-mail: tpicap-maitland@maitland.co.uk

 

 

About TP ICAP:

 

· TP ICAP brings together buyers and sellers in global financial, energy and commodities markets.

· It is the world's largest wholesale market intermediary, with a portfolio of businesses that provide broking services, data & analytics and market intelligence, trusted by clients around the world.

· We operate from offices in 26 countries, supporting award-winning brokers with market-leading technology.

 

Further information on TP ICAP and its activities is available on the Company's website: www.tpicap.com/investors

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKPBBKBKKKDB
Date   Source Headline
6th Jan 201710:54 amRNSPublication of a Prospectus
6th Jan 20177:00 amRNSTrading Update
5th Jan 20172:13 pmRNSHolding(s) in Company
4th Jan 201711:38 amRNSHolding(s) in Company
3rd Jan 20175:51 pmRNSTotal Voting Rights
30th Dec 20168:05 amRNSAdmission of new shares
30th Dec 20167:00 amRNSCompletion of transaction with NEX
28th Dec 201611:07 amRNSChange of Name
28th Dec 20167:00 amRNSStatement re transaction with NEX
9th Dec 20167:00 amRNSDividend Declaration
6th Dec 20161:40 pmRNSStatement re transaction with ICAP
1st Dec 201610:02 amRNSHolding(s) in Company
23rd Nov 201611:29 amRNSHolding(s) in Company
15th Nov 201612:09 pmRNSStatement re transaction with ICAP
4th Nov 20167:00 amRNSTrading Statement
1st Nov 201612:52 pmRNSDirector Declaration
3rd Oct 20162:34 pmRNSTP ICAP Global Executive Committee
3rd Oct 20162:29 pmRNSTullett Prebon Management Changes
3rd Oct 20169:55 amRNSTotal Voting Rights
27th Sep 20162:15 pmRNSAdditional Listing
26th Sep 20167:03 amRNSStatement re transaction with ICAP
12th Sep 20163:49 pmRNSPublication of Supplementary Prospectus
8th Sep 201612:20 pmRNSStatement on transaction with Tullett Prebon
8th Sep 201612:15 pmRNSStatement re transaction with ICAP
24th Aug 20162:15 pmRNSHolding(s) in Company
3rd Aug 20162:15 pmRNSDirector/PDMR Shareholding
2nd Aug 20169:08 amRNSNew Technology Centre, Belfast Northern Ireland
2nd Aug 20167:00 amRNSHalf-year Report
22nd Jul 20161:15 pmRNSStatement re transaction with ICAP
29th Jun 20166:00 pmRNSNotification of Interim Results
21st Jun 20166:25 pmRNSStatement re transaction with ICAP
20th Jun 201610:21 amRNSHolding(s) in Company
7th Jun 20167:09 amRNSStatement re. CMA announcement
6th Jun 20164:18 pmRNSHolding(s) in Company
16th May 201612:08 pmRNSPublication of Supplementary Prospectus
16th May 20167:13 amRNSIGBB FY 2016 results
13th May 201612:16 pmRNSDirectorate Change
13th May 201610:17 amRNSResult of AGM
12th May 20167:00 amRNSTrading Statement
6th May 20167:00 amRNSDirectorate Change
5th May 20164:41 pmRNSDirector/PDMR Shareholding
4th May 201612:51 pmRNSHolding(s) in Company
22nd Apr 20165:18 pmRNSDirector/PDMR Shareholding
19th Apr 20165:27 pmRNSDirector/PDMR Shareholding
5th Apr 20162:49 pmRNSPublication of Supplementary Prospectus
4th Apr 20164:48 pmRNSAnnual Financial Report
24th Mar 20162:16 pmRNSEGM Statement
1st Mar 201611:37 amRNSPublication of Prospectus
1st Mar 20167:00 amRNSFinal Results
1st Mar 20167:00 amRNSStatement re acquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.